TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Antibe Therapeutics Inc. (“Antibe” or the “Company”) announced that, in connection with its previously announced receivership proceedings, the Company ...

Sun Pharmaceutical Industries rose 1.14% to Rs 1,725.55 after its subsidiary, TARO Pharmaceuticals Inc., completed the 100% acquisition of Antibe Therapeutics Inc. of Canada for a total consideration ...

Mumbai: In a recent BSE filing, Sun Pharmaceutical Industries Limited has informed that TARO Pharmaceuticals Inc., a ...

Sun Pharmaceutical Industries Limited has announced the completion of its 100% acquisition of Antibe Therapeutics Inc., a ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs for pain and inflammation that fell into receivership last year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics and Citagenix segments.

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Antibe Therapeutics Inc. (“Antibe” or the “Company”) announced that, in connection with its previously announced receivership proceedings ...